Progress in the regulation of B cells in atherosclerotic stroke

doi:10.3969/j.issn.1672-6731.2020.01.004

Abstract

Abstract:

Atherosclerosis is one of the main pathological basis of ischemic stroke. Recent studies have found that arterial tertiary lymphoid organs (ATLOs) is rich in B lymphocytes, which play an important regulatory role in the formation and progress of atherosclerosis plaque through local immune response. Some B-cell regulatory factors can also reduce the volume of ischemic stroke cerebral infarction, which is expected to be a new treatment option for ischemic stroke. This paper aims to review the role and mechanism of B lymphocyte subsets in regulating the progress of atherosclerosis and ischemic stroke. It will be helpful to explore the immune mechanism and immunotherapeutic potential of the occurrence and progress of atherosclerosis and ischemic stroke.

Key words: Stroke, Atherosclerosis, B-lymphocytes, Immunotherapy, Review

摘要：

动脉粥样硬化是缺血性卒中的主要病理学基础。近年研究发现，动脉第三淋巴器官富含B细胞，可通过局部免疫应答对动脉粥样硬化斑块的形成与进展发挥重要调节作用；其中部分B细胞调控因子可使梗死灶体积缩小，有望成为缺血性卒中治疗的替代性选择。本文拟对B细胞亚群参与调控动脉粥样硬化和缺血性卒中进展的作用与机制进行综述，以助于探寻动脉粥样硬化、缺血性卒中发生发展的免疫机制及免疫治疗潜能。

关键词: 卒中, 动脉粥样硬化, B-淋巴细胞, 免疫疗法, 综述

ZOU Yu-tian, ZHANG Yan-lin, CAO Yong-jun. Progress in the regulation of B cells in atherosclerotic stroke[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(1): 15-21.

邹钰钿, 张艳林, 曹勇军. B细胞调控动脉粥样硬化性卒中研究进展[J]. 中国现代神经疾病杂志, 2020, 20(1): 15-21.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2020.01.004

https://journal11.magtechjournal.com/cjcnn/EN/Y2020/V20/I1/15

References

[1] Hansson GK, Jonasson L, Holm J, Claesson-Welsh L. Class Ⅱ MHC antigen expression in the atheroscerotic plaque:smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain[J]. Clin Exp Immunol, 1986, 64:261-268.
[2] Abdolmaleki F, Gheibi Hayat SM, Bianconi V, Johnston TP, Sahebkar A. Atherosclerosis and immunity:a perspective[J]. Trends Cardiovasc Med, 2019, 29:363-371.
[3] Jian Z, Liu R, Zhu X, Smerin D, Zhong Y, Gu L, Fang W, Xiong X. The involvement and therapy target of immune cells after ischemic stroke[J]. Front Immunol, 2019, 10:2167.
[4] Srikakulapu P, McNamara CA. B cells and atherosclerosis[J]. Am J Physiol Heart Circ Physiol, 2017, 312:H1060-1067.
[5] Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. Adventitial infiltrates associated with advanced atherosclerotic plaques:structural organization suggests generation of local humoral immune responses[J]. J Pathol, 2001, 193:263-269.
[6] Yin C, Mohanta SK, Srikakulapu P, Weber C, Habenicht AJ. Artery tertiary lymphoid organs:powerhouses of atherosclerosis immunity[J]. Front Immunol, 2016, 7:387.
[7] Baumgarth N. B-1 cell heterogeneity and the regulation of natural and antigen-induced IgM production[J]. Front Immunol, 2016, 7:324.
[8] Hilgendorf I, Theurl I, Gerhardt LM, Robbins CS, Weber GF, Gonen A, Iwamoto Y, Degousee N, Holderried TA, Winter C, Zirlik A, Lin HY, Sukhova GK, Butany J, Rubin BB, Witztum JL, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity[J]. Circulation, 2014, 129:1677-1687.
[9] Vaughan AT, Roghanian A, Cragg MS. B cells:masters of the immunoverse[J]. Int J Biochem Cell Biol, 2011, 43:280-285.
[10] Hamel KM, Liarski VM, Clark MR. Germinal center B-cells[J]. Autoimmunity, 2012, 45:333-347.
[11] Lund FE. Cytokine-producing B lymphocytes:key regulators of immunity[J]. Curr Opin Immunol, 2008, 20:332-338.
[12] Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, Wingfield PT, Kim SH, Egwuagu CE. Interleukin-35 induces regulatory B cells that suppress autoimmune disease[J]. Nat Med, 2014, 20:633-641.
[13] Huan T, Zhang B, Wang Z, Joehanes R, Zhu J, Johnson AD, Ying S, Munson PJ, Raghavachari N, Wang R, Liu P, Courchesne P, Hwang SJ, Assimes TL, McPherson R, Samani NJ, Schunkert H, Meng Q, Suver C, O'Donnell CJ, Derry J, Yang X, Levy D; Coronary ARteryDIsease Genome Wide Replication and Meta-Analysis (CARDIoGRAM) Consortium, International Consortium for Blood Pressure GWAS (ICBP). A systems biology framework identifies molecular underpinnings of coronary heart disease[J]. Arterioscler Thromb Vasc Biol, 2013, 33:1427-1434.
[14] Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemicmice[J]. J Clin Invest, 2002, 109:745-753.
[15] Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice[J]. Arterioscler Thromb Vasc Biol, 2002, 22:1892-1898.
[16] Sage AP, Tsiantoulas D, Binder CJ, Mallat Z. The role of B cells in atherosclerosis[J]. Nat Rev Cardiol, 2019, 16:180-196.
[17] Bernelot Moens SJ, van Leuven SI, Zheng KH, Havik SR, Versloot MV, van Duivenvoorde LM, Hahne M, Stroes ES, Baeten DL, Hamers AA. Impact of the B cell growth factor APRIL on the qualitative and immunological characteristics of atherosclerotic plaques[J]. PLoS One, 2016, 11:E0164690.
[18] Hosseini H, Li Y, Kanellakis P, Tay C, Cao A, Liu E, Peter K, Tipping P, Toh BH, Bobik A, Kyaw T. Toll-like receptor (TLR) 4 and MyD88 are essential for atheroprotection by peritoneal B1a B cells[J]. J Am Heart Assoc, 2016, 5:E002947.
[19] Chen A, Geng Y, Ke H, Constant L, Yan Z, Pan Y, Lee P, Tan I, Williams K, George S, Munirathinam G, Reardon CA, Getz GS, Wang B, Zheng G. Cutting edge:dexamethasone potentiates the responses of both regulatory T cells and B-1 cells to antigen immunization in the ApoE(-/-) mouse model of atherosclerosis[J]. J Immunol, 2014, 193:35-39.
[20] Grimm M, Tischner D, Troidl K, AlbarránJuárez J, Sivaraj KK, FerreirósBouzas N, Geisslinger G, Binder CJ, Wettschureck N. S1P2/G12/13 signaling negatively regulates macrophage activation and indirectly shapes the atheroprotective B1-cell population[J]. Arterioscler Thromb Vasc Biol, 2016, 36:37-48.
[21] Gruber S, Hendrikx T, Tsiantoulas D, Ozsvar-Kozma M, Göderle L, Mallat Z, Witztum JL, Shiri-Sverdlov R, Nitschke L, Binder CJ. Sialic acid-binding immunoglobulin-like lectin G promotes atherosclerosis and liver inflammation by suppressing the protective functions of B-1 cells[J]. Cell Rep, 2016, 14:2348-2361.
[22] Karper JC, de Jager SC, Ewing MM, de Vries MR, Bot I, van Santbrink PJ, Redeker A, Mallat Z, Binder CJ, Arens R, Jukema JW, Kuiper J, Quax PH. An unexpected intriguing effect of Toll-like receptor regulator RP105(CD180) on atherosclerosis formation with alterations on B-cell activation[J]. Arterioscler Thromb Vasc Biol, 2013, 33:2810-2817.
[23] Chen L, Ishigami T, Nakashima-Sasaki R, Kino T, Doi H, Minegishi S, Umemura S. Commensal microbe-specific activation of B2 cell subsets contributes to atherosclerosis development independently of lipid metabolism[J]. E Bio Medicine, 2016, 13:237-247.
[24] Tay C, Liu YH, Hosseini H, Kanellakis P, Cao A, Peter K, Tipping P, Bobik A, Toh BH, Kyaw T. B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation[J]. Cardiovasc Res, 2016, 111:385-397.
[25] Rattik S, Mantani PT, Yao Mattisson I, Ljungcrantz I, Sundius L, Björkbacka H, Terrinoni M, Lebens M, Holmgren J, Nilsson J, Wigren M, NordinFredrikson G. B cells treated with CTB-p210 acquire a regulatory phenotype in vitro and reduce atherosclerosis in apolipoprotein E deficient mice[J]. Vascul Pharmacol, 2018, 111:54-61.
[26] Ponnuswamy P, Joffre J, Herbin O, Esposito B, Laurans L, Binder CJ, Tedder TF, Zeboudj L, Loyer X, Giraud A, Zhang Y, Tedgui A, Mallat Z, Ait-Oufella H. Angiotensin Ⅱ synergizes with BAFF to promote atheroprotective regulatory B cells[J]. Sci Rep, 2017, 7:4111.
[27] Shikatani EA, Besla R, Ensan S, Upadhye A, Khyzha N, Li A, Emoto T, Chiu F, Degousee N, Moreau JM, Perry HM, Thayaparan D, Cheng HS, Pacheco S, Smyth D, Noyan H, Zavitz CC, Bauer CM, Hilgendorf I, Libby P, Swirski FK, Gommerman JL, Fish JE, Stampfli MR, Cybulsky MI, Rubin BB, Paige CJ, Bender TP, McNamara CA, Husain M, Robbins CS. c-Myb exacerbates atherosclerosis through regulation of protective IgM-producing antibody-secreting cells[J]. Cell Rep, 2019, 27:2304-2312.
[28] Centa M, Jin H, Hofste L, Hellberg S, Busch A, Baumgartner R, Verzaal NJ, Lind Enoksson S, Perisic Matic L, Boddul SV, Atzler D, Li DY, Sun C, Hansson GK, Ketelhuth DFJ, Hedin U, Wermeling F, Lutgens E, Binder CJ, Maegdesfessel L, Malin SG. Germinal center-derived antibodies promote atherosclerosis plaque size and stability[J]. Circulation, 2019, 139:2466-2482.
[29] Sage AP, Nus M, BagchiChakraborty J, Tsiantoulas D, Newland SA, Finigan AJ, Masters L, Binder CJ, Mallat Z. X-box binding protein-1 dependent plasma cell responses limit the development of atherosclerosis[J]. Circ Res, 2017, 121:270-281.
[30] Tsiantoulas D, Bot I, Ozsvar-Kozma M, Göderle L, Perkmann T, Hartvigsen K, Conrad DH, Kuiper J, Mallat Z, Binder CJ. Increased plasma IgE accelerate atherosclerosis in secreted IgM deficiency[J]. Cir Res, 2017, 120:78-84.
[31] Jeng JS, Tang SC, Liu HM. Epidemiology, diagnosis and management of intracranial atherosclerotic disease[J]. Expert Rev Cardiovasc Ther, 2010, 8:1423-1432.
[32] Mantani PT, Ljungcrantz I, Andersson L, Alm R, Hedblad B, Björkbacka H, Nilsson J, Fredrikson GN. Circulating CD40 + and CD86 + B cell subsets demonstrate opposing associations with risk of stroke[J]. Arterioscler Thromb Vasc Biol, 2014, 34:211-218.
[33] Selvaraj UM, Poinsatte K, Torres V, Ortega SB, Stowe AM. Heterogeneity of B cell functions in stroke-related risk, prevention, injury, and repair[J]. Neurotherapeutics, 2016, 13:729-747.
[34] Selvaraj UM, Ortega SB, Hu R, Gilchrist R, Kong X, Partin A, Plautz EJ, Klein RS, Gidday JM, Stowe AM. Preconditioning-induced CXCL12 upregulation minimizes leukocyte infiltration after stroke in ischemia-tolerant mice[J]. J Cereb Blood Flow Metab, 2017, 37:801-813.
[35] Serebrovskaya TV, Nikolsky IS, Nikolska VV, Mallet RT, Ishchuk VA. Intermittent hypoxia mobilizes hematopoietic progenitors and augments cellular and humoral elements of innate immunity in adult men[J]. High Alt Med Biol, 2011, 12:243-252.
[36] Elphick GF, Wieseler-Frank J, Greenwood BN, Campisi J, Fleshner M. B-1 cell (CD5+/CD11b+) numbers and nIgM levels are elevated in physically active vs. sedentary rats[J]. J Appl Physiol, 2003, 95:199-206.
[37] Shin JA, Park EM, Choi JS, Seo SM, Kang JL, Lee KE, Cho S. Ischemic preconditioning-induced neuroprotection is associated with differential expression of IL-1beta and IL-1 receptor antagonist in the ischemic cortex[J]. J Neuroimmunol, 2009, 217:14-19.
[38] Chen Y, Bodhankar S, Murphy SJ, Vandenbark AA, Alkayed NJ, Offner H. Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice[J]. Metab Brain Dis, 2012, 27:487-493.
[39] Ren X, Akiyoshi K, Dziennis S, Vandenbark AA, Herson PS, Hurn PD, Offner H. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke[J]. J Neurosci, 2011, 31:8556-8563.
[40] Offner H, Hurn PD. A novel hypothesis:regulatory B lymphocytes shape outcome from experimental stroke[J]. Transl Stroke Res, 2012, 3:324-330.
[41] Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice[J]. Metab Brain Dis, 2014, 29:59-73.
[42] Doyle KP, Quach LN, Solé M, Axtell RC, Nguyen TV, Soler-Llavina GJ, Jurado S, Han J, Steinman L, Longo FM, Schneider JA, Malenka RC, Buckwalter MS. B-lymphocyte-mediated delayed cognitive impairment following stroke[J]. J Neurosci, 2015, 35:2133-2145.
[43] Doyle KP, Buckwalter MS. Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia[J]? Brain Behav Immun, 2017, 64:1-8.
[44] Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van Vré E, Esposito B, Vilar J, Sirvent J, Van Snick J, Tedgui A, Tedder TF, Mallat Z. B cell depletion reduces the development of atherosclerosis in mice[J]. J Exp Med, 2010, 207:1579-1587.
[45] Kyaw T, Cui P, Tay C, Kanellakis P, Hosseini H, Liu E, Rolink AG, Tipping P, Bobik A, Toh BH. BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice[J]. PLoS One, 2013, 8:E60430.
[46] Sage AP, Mallat Z. Readapting the adaptive immune response-therapeutic strategies for atherosclerosis[J]. Br J Pharmacol, 2017, 174:3926-3939.
[47] Seifert HA, Vandenbark AA, Offner H. Regulatory B cells in experimental stroke[J]. Immunology, 2018, 154:169-177.

Please choose a citation manager

Content to export